CareDx, Inc. - Common Stock (OQ:CDNA)

Jan 13, 2025 07:00 am ET
CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024.
Dec 18, 2024 07:05 am ET
CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
Dec 11, 2024 07:00 am ET
CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx will partner with TC BioPharm to perform pharmacokinetic analysis using its AlloCell™ solution in the ACHIEVE clinical trial.
Dec 11, 2024 06:00 am ET
TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
EDINBURGH, Scotland, Dec. 11, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced a partnership with CareDx, Inc. (NASDAQ: CDNA) The Transplant Company™ who will perform pharmacokinetic analysis using its AlloCell™ solution in the ACHIEVE clinical trial.
Nov 12, 2024 07:05 am ET
CareDx to Participate in Upcoming Investor Conferences
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences.
Nov 04, 2024 04:05 pm ET
CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance
CareDx, Inc. (Nasdaq: CDNA) – today announced financial results for the third quarter ended September 30, 2024.
Oct 23, 2024 07:00 am ET
CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C Technology
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and co
Oct 21, 2024 07:00 am ET
CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data and product enhancements being presented at the 50th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI). The meeting takes place in Anaheim, California, from October 21-25, 2024.
Oct 15, 2024 06:00 am ET
CareDx Reports Preliminary Financial Results for Third Quarter 2024
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —today reported preliminary financial results for the third quarter ended September 30, 2024.
Oct 11, 2024 07:47 pm ET
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
NEW ORLEANS, Oct. 11, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into CareDx, Inc. (NasdaqGM: CDNA).
Oct 11, 2024 04:30 pm ET
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on October 8, 2024, CareDx granted to Jing Huang, the Company’s newly appointed Chief Data and AI Officer, 15,547 restricted stock units (“RSUs”) and an option to purchase 22,248 shares of CareDx common stock (“Option”), as an inducement material to entering into employment with CareDx, pursuant to the Company’s 2019 In
Oct 09, 2024 07:05 am ET
CareDx Appoints Jing Huang Chief Data and AI Officer
CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data and Artificial Intelligence (AI) Officer. Huang will lead key data science initiatives that are a part of the Company’s long-term strategic growth plan. CareDx intends to share its long-term growth strategy during an Investor Day on October 15, 2024.
Oct 08, 2024 04:05 pm ET
CareDx to Host Investor Day on October 15, 2024
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the Company will be hosting an Investor Day on October 15, 2024, in New York City, New York, starting at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time. The event will feature presentations by members of the Company's leadership team.
Oct 08, 2024 06:05 am ET
CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Department of Justice (DOJ) has concluded its investigation into CareDx with no finding of wrongdoing and declined to take any further action.
Sep 13, 2024 08:35 pm ET
CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on September 12, 2024, CareDx granted an option to purchase 100,651 shares of CareDx’s common stock (the “Kennedy Inducement Option”) and 70,101 restricted stock units (the “Kennedy Inducement RSUs”) to Keith S. Kennedy, CareDx’s newly appointed Chief Operating Officer, and granted an option to purchase 75,488 shares of
Sep 13, 2024 08:33 pm ET
CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with CareDx, on September 12, 2024, 14 new employees were awarded restricted stock units (RSUs) for an aggregate of 44,000 shares of common stock. The RSUs were granted pursuant to the Company’s 2019 Inducement Equity Incentive Plan, which was approved by the Compens
Sep 12, 2024 07:01 am ET
CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the appointment of two senior executives who will lead key initiatives as the Company advances its long-term strategic growth plan. CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024.
Aug 16, 2024 02:10 pm ET
CareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap Testing
CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ – today announced that the Centers for Medicare and Medicaid Services (CMS) has announced its plan to retire a draft LCD that would have restricted coverage for non-invasive blood-based surveillance testing for allograft rejecti
Jul 16, 2024 10:30 am ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CareDx, Inc. (NASDAQ: CDNA)
NEW YORK, July 16, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating CareDx, Inc. (NASDAQ: CDNA) on behalf of the company's shareholders.  The investigation seeks to determine whether CareDx's directors breached their fiduciary duties in connection with recent corporate actions.
Jun 03, 2024 07:05 am ET
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced in conjunction with the 2024 American Transplant Congress, the publication in Nature Medicin
May 30, 2024 07:05 am ET
AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data to be presented at the 2024 American Transplant Congress (ATC) being held June 1-5 in Philadelphia.
Apr 19, 2024 04:05 pm ET
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 15, 2024, CareDx granted an option to purchase 700,706 shares of CareDx’s common stock (the “Inducement Option”) and 487,804 restricted stock units (the “Inducement RSUs” ) to John Hanna, CareDx’s newly appointed President and Chief Executive Officer. The Inducement Option and the Inducement RSUs were approved
Apr 16, 2024 04:02 pm ET
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company’s Board of Directors, effective April 15, 2024.
Apr 09, 2024 07:00 am ET
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx and study collaborators will be presenting the latest data featuring CareDx’s cardiothoracic portfolio at the International Society for Heart and Lung Transplantation (ISHLT) 44th Annual Meeting & Scientific Sessions, taking place from April 10-13 in Prague, Czech Republic.
Mar 11, 2024 04:10 pm ET
CareDx Appoints Bryan Riggsbee to Its Board of Directors
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that Bryan Riggsbee joins CareDx’s Board of Directors, effective March 11, 2024.
Feb 28, 2024 04:05 pm ET
CareDx Announces Fourth Quarter and Full Year 2023 Financial Results
CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2023.
Feb 27, 2024 04:05 pm ET
CareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors Conference
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the company will be participating in the upcoming Raymond James & Associates’ 45th Annual Institutional Investors Conference.
Feb 21, 2024 04:05 pm ET
CareDx to Report Fourth Quarter and Full Year 2023 Financial Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Feb 21, 2024 07:00 am ET
CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings
CareDx, Inc. (Nasdaq: CDNA) —The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it will be showcasing the breadth of its specialized digital solutions and the latest advancements in its cellular therapy and transplant monitoring pipeline at the 2024 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, being held February 21-25 in San Antonio, Texas
Jan 26, 2024 09:45 pm ET
CareDx Issues Statement in Patent Infringement Case
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the jury verdict in the patent litigation brought by Natera, Inc. (Nasdaq: NTRA).
Jan 11, 2024 04:05 pm ET
CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence and the fifth consecutive year as the Distinguished Founder’s Circle Sponsor for the Annual American Society of Transplant Surgeons (ASTS) Winter Symposium being held January 11 - 14, 2024 in Miami, Florida.
Jan 09, 2024 07:00 am ET
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported preliminary financial results for the fourth quarter and full year ended December 31, 2023.
Dec 19, 2023 07:00 am ET
CareDx Joins Forces with the National Foundation for Transplants to Improve Post-Transplant Medication Adherence
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is joining forces with the National Foundation for Transplants (NFT) in offering its Transplant Pharmacy services to NFT patient members to help them manage the complexity of post-transplant medication adherence.
Nov 08, 2023 04:05 pm ET
CareDx Reports Third Quarter 2023 Results
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today reported financial results for the third quarter ended September 30, 2023.
Nov 02, 2023 04:05 pm ET
CareDx to Report Third Quarter 2023 Financial Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the third quarter 2023 after market close on Wednesday, November 8th, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Nov 01, 2023 04:02 pm ET
CareDx Announces CEO Transition
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced today that Dr. Reginald Seeto will be stepping down from his position as Chief Executive Officer and President and resigning as a Director of the Board effective November 1, 2023, and will transition to the role of Senior Advisor to the Chairperson.
Oct 17, 2023 07:00 am ET
CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 49th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) being held in San Antonio, Texas from October 16-20, 2023.
Oct 03, 2023 06:00 pm ET
CareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed Patents
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – acknowledges the Supreme Court’s decision not to review the Federal Circuit’s decision on the patent eligibility of three Stanford-licensed patents. CareDx notes the decision does not impact the Company’s ability to continue providing AlloSure® donor-derived cell-free DNA (dd-cfDNA).
Sep 19, 2023 07:00 am ET
CareDx To Present at the 2023 Cantor Global Healthcare Conference
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the 2023 Cantor Global Healthcare Conference.
Sep 14, 2023 02:00 am ET
CareDx Advances Global Transplant Patient Care at ESOT Congress 2023
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 European Society for Organ Transplantation (ESOT) Congress taking place September 17-20, 2023, in Athens, Greece.
Aug 31, 2023 07:00 am ET
CareDx To Present at the H.C. Wainwright 25th Annual Global Investment Conference
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference.
Aug 17, 2023 07:00 am ET
CareDx Hosts Second Annual MEET Digital Health User Conference to Showcase Latest Innovations to Enhance Transplant Patient Care
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its second annual digital health user conference, the Management Expert Exchange in Transplantation (MEET) Conference, taking place August 27-29 in Dallas, Texas.
Aug 11, 2023 07:00 am ET
CareDx Comments on Issuance of Proposed LCD for Molecular Testing for Solid Allograft Rejection
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today commented on the issuance of proposed changes to the Local Coverage Determination (LCD) MolDX Molecular Testing for Solid Organ Allograft Rejection that covers AlloSure®, AlloMap® and HeartCare.
Aug 08, 2023 04:05 pm ET
CareDx Reports Second Quarter 2023 Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the second quarter ended June 30, 2023.
Aug 07, 2023 11:08 am ET
CareDx Announces District Court Judge Bars Natera from Falsely Advertising and Overstating the Scientific Performance of its Prospera Transplant Test
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the United States District Court for the District of Delaware (the “District Court”) issued an injunction prohibiting Natera (Nasdaq: NTRA) from continuing to falsely advertise and overstate the scientific performance of its Prospera transplant test. A copy of the injunction is available
Aug 03, 2023 07:00 am ET
CareDx to Report Second Quarter 2023 Financial Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2023 after market close on Tuesday, August 8th, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Aug 02, 2023 07:00 am ET
CareDx’s HeartCare Multimodality Service Receives Medicare Coverage for Heart Transplant Surveillance
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced Medicare coverage for HeartCare, a multimodality testing service that includes both AlloMap® Heart and AlloSure® Heart, in a given patient encounter, for heart transplant surveillance. Coverage is effective April 1, 2023. AlloMap Heart and AlloSure Heart are also covered by Medicare individually.
Jul 25, 2023 07:00 am ET
CareDx Acquires MediGO, an Organ Transplant Supply Chain and Logistics Company
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the acquisition of MediGO, Inc. in a strategic move to expand its digital health portfolio to serve the organ procurement organization (OPO) market while also bolstering its pre-transplant offerings aimed at shortening transplant wait times and increasing access to donated organs.
Jul 17, 2023 11:42 pm ET
CareDx Applauds District Court Decision to Uphold Jury Verdict that Natera Falsely Advertised its Prospera Transplant Test
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the United States District Court for the District of Delaware (the “District Court”) decision upheld and reaffirmed the March 2022 jury verdict finding that Natera (Nasdaq: NTRA) violated the Lanham Act by falsely advertising the scientific performance of its Prospera transplant test.
Jul 11, 2023 07:00 am ET
CareDx’s AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx’s AlloSure® Lung donor-derived cell-free DNA (dd-cfDNA) molecular testing service has received Medicare coverage.
Jun 01, 2023 08:00 am ET
CareDx Demonstrates Innovation Leadership at 2023 Transplant Congress
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 American Transplant Congress (ATC) with 65 scientific presentations. CareDx will also be hosting a satellite symposium1 and sponsoring the Women’s Networking Event. The ATC meeting takes place June 3-7 in San Diego, California.
Jun 01, 2023 07:00 am ET
CareDx to Participate in Upcoming Investor Conferences
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences.
May 24, 2023 08:00 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of CareDx, Inc. and Encourages Long-Term CDNA Stockholders to Contact the Firm
Kaskela Law LLC announces that it is investigating CareDx, Inc. (“CareDx”) (NASDAQ: CDNA) on behalf of the Company’s long-term stockholders. Recently a shareholder class action complaint was filed against CareDx on behalf of certain investors who...
May 16, 2023 07:00 am ET
CareDx Showcases Digital Health Portfolio at 31st Annual UNOS Transplant Management Forum
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will showcase its digital health portfolio and host a symposium which addresses barriers in access to transplantation at the 31st Annual UNOS Transplant Management Forum (TMF) taking place May 16-18 in Denver, Colorado. CareDx is the leading Diamond level sponsor of this year’s UNOS TMF.
May 10, 2023 04:05 pm ET
CareDx Reports First Quarter 2023 Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the first quarter ended March 31, 2023.
May 08, 2023 07:01 am ET
CareDx to Report First Quarter 2023 Financial Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 10, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Apr 25, 2023 06:01 am ET
CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will showcase the latest developments across its AlloSeq®* portfolio during the 36th European Immunogenetics and Histocompatibility Conference taking place April 26-29 in Nantes, France.
Apr 19, 2023 09:00 am ET
SHAREHOLDER ALERT: Morris Kandinov Investigating LFST, BRY, CDNA, and OPEN; Shareholders are Encouraged to Contact the Firm
National law firm Morris Kandinov is investigating the actions of the officers and board of directors of LifeStance Health Group, Inc., Berry Corporation, CareDx, Inc., and Opendoor Technologies Inc. If you are a current owner of shares of any of...
Apr 19, 2023 07:01 am ET
CareDx Showcases Leadership with Over 55 Oral Presentations and Posters at the 43rd Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation
“We are exceedingly proud to have a remarkable presence at this year’s ISHLT meeting with HeartCare data showing significant clinical benefits and compelling data supporting the advancement of AlloSure Lung into clinical practice,” said Reg Seeto, CEO and President of CareDx. “The significant body of evidence presented at ISHLT demonstrates the value of routinely incorporating CareDx’s non-invasive molecular solutions in heart and lung transplant clinical decision making.”
Apr 06, 2023 07:01 am ET
National Kidney Foundation Honors CareDx with Corporate Citizenship Award for its Commitment to the Transplant Community
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the National Kidney Foundation honored CareDx with a corporate citizenship award during its 41st Annual Kidney Ball held on March 31, 2023, in Washington, D.C.
Apr 05, 2023 06:55 am ET
CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation
CareDx, Inc. (Nasdaq: CDNA) and Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO) – today announced an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs.
Apr 05, 2023 06:50 am ET
CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation
CareDx, Inc. (Nasdaq: CDNA) and Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO) -- today announced an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs. CareDx will...
Mar 23, 2023 07:01 am ET
CareDx Presents Latest Advancements at 12th Congress of the International Pediatric Transplant Association
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its gold-level sponsorship and participation at the 12th Congress of the International Pediatric Transplant Association (IPTA) taking place March 25-28, 2023, in Austin, Texas.
Mar 10, 2023 10:50 pm ET
CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into CareDx, Inc. (NasdaqGM: CDNA).
Mar 07, 2023 07:01 am ET
The American Society of Transplant Surgeons Position Statement Supports Use of CareDx’s AlloSure Kidney for Organ Transplant Surveillance
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the issuance of a new position statement by the American Society of Transplant Surgeons (ASTS) supporting the use of CareDx’s AlloSure® Kidney for organ transplant surveillance, and AlloSure Heart and AlloMap® Heart.
Mar 06, 2023 04:32 pm ET
CareDx Update Regarding Raymond James & Associates’ Conference
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company has determined not to participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference scheduled for later today in light of scheduling conflicts. The company looks forward to providing its next corporate update in the near term.
Mar 06, 2023 07:01 am ET
CareDx To Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference.
Mar 03, 2023 07:01 am ET
CareDx Comments on MolDX Publication of New Billing and Coding Article
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today commented on the release of a Billing Article related to MolDX Molecular Testing for Solid Organ Allograft Rejection that covers AlloSure® and AlloMap®. The Billing Article is effective March 31, 2023.
Mar 01, 2023 07:01 am ET
CareDx Key Supporter of the National Kidney Foundation’s Annual Kidney Patient Summit
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced that it is sponsoring the National Kidney Foundation (NKF) Annual Kidney Patient Summit taking place on Capitol Hill on March 1-2, 2023.
Feb 27, 2023 04:01 pm ET
CareDx Reports Fourth Quarter and Full Year 2022 Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the fourth quarter and full year ended December 31, 2022.
Feb 24, 2023 09:50 pm ET
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
NEW ORLEANS, Feb. 24, 2023 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into CareDx, Inc. (NasdaqGM: CDNA).  
Feb 22, 2023 07:01 am ET
CareDx Showcases Clinical Value of Multimodality and AI Innovation at the American Society of Transplantation Cutting Edge of Transplantation Meeting
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced that it is showcasing the clinical value of multimodality and artificial intelligence innovation at the annual American Society of Transplantation Cutting Edge of Transplantation (CEoT) meeting taking place February 23-25, in Scottsdale, Arizona.
Feb 21, 2023 04:01 pm ET
CareDx to Report Fourth Quarter and Full Year 2022 Financial Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2022 after market close on Monday, February 27, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Feb 16, 2023 07:01 am ET
CareDx Showcases Latest Advancements in Cellular Transplant and Therapy Including Specialized Digital Health Solutions at the 2023 Tandem Meetings
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced that it will be presenting its latest solutions to support the cellular transplant and therapy ecosystem at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® taking place February 15-19 in Orlando, Florida.
Feb 13, 2023 10:54 am ET
CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into CareDx, Inc. (NasdaqGM: CDNA).
Jan 26, 2023 07:01 am ET
JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Journal of the American College of Cardiology (JACC): Heart Failure has published a
Jan 11, 2023 07:01 am ET
CareDx Fosters Transplant Innovation as Distinguished Founder’s Circle Sponsor for the 23rd Annual American Society of Transplant Surgeons State of the Art Winter Symposium
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced its leading participation and top spot, for the fourth consecutive year, as a Distinguished Founder’s Circle Sponsor for the 23rd Annual ASTS (American Society of Transplant Surgeons) State of the Art Winter Symposium, taking place January 12-15, in Miami, Florida.
Jan 09, 2023 07:00 am ET
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported preliminary financial results for the fourth quarter and full year ended December 31, 2022.
Dec 30, 2022 10:50 pm ET
CAREDX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CareDx, Inc. - CDNA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into CareDx, Inc. (NasdaqGM: CDNA).
Dec 21, 2022 06:00 pm ET
New ISHLT Guidelines Support Use of CareDx’s HeartCare Solutions, AlloMap and AlloSure, in Routine Monitoring of Heart Transplant Patients
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the publication1 of new guidelines by the International Society for Heart and Lung Transplantation (ISHLT) supporting the use of CareDx’s non-invasive molecular surveillance portfolio.
Dec 16, 2022 09:50 pm ET
CAREDX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CareDx, Inc. - CDNA
NEW ORLEANS, Dec. 16, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into CareDx, Inc. (NasdaqGM: CDNA).
Dec 14, 2022 07:00 am ET
Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Grace E. Colón, Ph.D., to its Board of Directors. Dr. Colón has more than 25...
Dec 06, 2022 08:01 am ET
CareDx Announces $50 Million Stock Repurchase Program
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that its Board of Directors has authorized a common stock repurchase program of up to $50 million of shares over a period of up to 24 months.
Dec 05, 2022 06:30 pm ET
CAREDX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CareDx, Inc. - CDNA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into CareDx, Inc. (NasdaqGM: CDNA).
Dec 01, 2022 08:15 am ET
Independent Prospective Study Defines Reference Range for CareDx’s AlloSure for Long-Term Lung Transplant Surveillance
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the results of a new study published in Transplantation Direct1 which establishes a reference baseline when using AlloSure® Lung in the long-term surveillance of lung transplant patients.
Nov 11, 2022 07:01 am ET
CareDx Committed to Delivering Clinical Innovation to the Transplant Patient and Physician Community
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the five-year anniversary of AlloSure®, the groundbreaking, non-invasive donor-derived cell-free DNA (dd-cfDNA) surveillance solution used to measure allograft injury in solid organ transplant recipients. AlloSure along with AlloMap® represent disruptive innovations in the field of solid organ transplant.
Nov 04, 2022 07:00 am ET
CareDx To Participate in Upcoming Investor Conferences
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences.
Nov 03, 2022 04:01 pm ET
CareDx Reports Third Quarter 2022 Results
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today reported financial results for the third quarter ended September 30, 2022.
Nov 02, 2022 07:01 am ET
CareDx Demonstrates Power of AlloSure and Digital Health Transplant Solutions at American Society of Nephrology Kidney Week
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will be sharing the latest data on AlloSure® Kidney and its patient-centered digital health solutions at the American Society of Nephrology (ASN) Kidney Week 2022 meeting being held November 3 - 6 in Orlando, Florida.
Nov 01, 2022 07:01 am ET
Independent Longitudinal Study Finds CareDx’s AlloSure Detects Early Signs of Rejection in Pediatric Kidney Transplant Patients
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the results of a new study published in the Clinical Journal of the American Society of Nephrology (CJASN)1 showing that CareDx’s AlloSure® Kidney donor-derived cell-free DNA (dd-cfDNA) solution identifies early signs of allograft rejection and BK virus infection in pediatric kidney transplant patients.
Oct 27, 2022 07:01 am ET
CareDx Congratulates C-Path's Transplant Therapeutics Consortium and Paris Transplant Group for Receiving EMA Draft Qualification for iBox Scoring System
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today congratulates C-Path’s Transplant Therapeutics Consortium and the Paris Transplant Group for their leadership in gaining European Medicine Agency (EMA) draft qualification1 for the iBox® Scoring System as a secondary endpoint in kidney transplant clinical trials.
Oct 26, 2022 07:30 am ET
CareDx to Report Third Quarter 2022 Financial Results
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 3, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Oct 26, 2022 07:01 am ET
CareDx Joins Forces with National Kidney Foundation and Honor the Gift Coalition to Host Immuno Bill Webinar for Kidney Transplant Patients
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx is hosting a webinar with the National Kidney Foundation and Honor the Gift Coalition to help patients navigate Medicare enrollment associated with the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020. Often referred to as the "Immuno Bill", the Bill becomes effective January 1, 2023.
Oct 25, 2022 07:01 am ET
CareDx Presents Latest Data on AlloSeq NGS Solutions and Transplant Innovation at the American Society for Histocompatibility and Immunogenetics Annual Meeting
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its leading presence as a Diamond Level sponsor at the 48th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) being held in Las Vegas, Nevada from October 24 to October 28.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.